NYSE - Delayed Quote USD

Eli Lilly and Company (LLY)

比較

829.74

-17.09

(-2.02%)

收市：10月31日下午4:00 [EDT]

830.00

+0.26

(+0.03%)

收市後：10月31日下午7:59 [EDT]

主要活動

進階圖表

Loading Chart for LLY

9/21 12:03 PM

DELL

前收市價 846.83
開市 836.51
買盤 827.00 x 900
賣出價 828.99 x 800
今日波幅 825.24 - 853.43
52 週波幅 561.65 - 972.53
成交量 5,527,571
平均成交量 3,114,620
市值 (當日) 787.685十億
Beta 值 (5 年，每月) 0.42
市盈率 (最近 12 個月) 89.03
每股盈利 (最近 12 個月) 9.32
業績公佈日 2024年10月30日
遠期股息及收益率 5.20 (0.61%)
除息日 2024年11月15日
1 年預測目標價 1,024.52

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

www.lilly.com

43,000